TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-554-4484
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees105
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions
What is TG Therapeutics' stock symbol?
TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."
How were TG Therapeutics' earnings last quarter?
TG Therapeutics Inc (NASDAQ:TGTX) posted its quarterly earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.01. The biopharmaceutical company earned $0.04 million during the quarter, compared to analysts' expectations of $0.04 million. TG Therapeutics had a negative net margin of 99,488.13% and a negative return on equity of 496.99%. View TG Therapeutics' Earnings History.
When is TG Therapeutics' next earnings date?
What price target have analysts set for TGTX?
6 brokers have issued 1-year target prices for TG Therapeutics' stock. Their predictions range from $8.00 to $27.00. On average, they expect TG Therapeutics' stock price to reach $15.6667 in the next twelve months. This suggests a possible upside of 134.5% from the stock's current price. View Analyst Price Targets for TG Therapeutics.
What is the consensus analysts' recommendation for TG Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TG Therapeutics.
What are Wall Street analysts saying about TG Therapeutics stock?
Here are some recent quotes from research analysts about TG Therapeutics stock:
- 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (8/15/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $17 PT. On the 1Q call, TG discussed recent pipeline progress, including the interim data for umbralisib in marginal zone lymphoma (MZL) that were presented at AACR last month and potential updates over the rest of 2019 and early 2020. After positive interim data for umbralisib in MZL, another major milestone will be discussing recent positive MZL data with the FDA. The final MZL data are to be presented toward the end of 2019 (we think potentially at the meantime, the company plans to present an update at ASCO and meet with the FDA to discuss accelerated approval." (5/13/2019)
- 3. HC Wainwright analysts commented, "Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 30% POS for ublituximab in NHL, a 35% POS for umbralisib in 40% POS for ublituximab in MS." (4/12/2019)
Has TG Therapeutics been receiving favorable news coverage?
News headlines about TGTX stock have trended positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TG Therapeutics earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for TG Therapeutics.
Who are some of TG Therapeutics' key competitors?
Some companies that are related to TG Therapeutics include Agios Pharmaceuticals (AGIO), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Xencor (XNCR), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS), Zogenix (ZGNX), Uniqure (QURE), Zai Lab (ZLAB), Akcea Therapeutics (AKCA), Cambrex (CBM), Biohaven Pharmaceutical (BHVN), Portola Pharmaceuticals (PTLA), Apellis Pharmaceuticals (APLS) and Ligand Pharmaceuticals (LGND).
What other stocks do shareholders of TG Therapeutics own?
Who are TG Therapeutics' key executives?
TG Therapeutics' management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 53)
- Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 37)
- Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
- Mr. Adam Waldman, Chief Commercial Officer
Who are TG Therapeutics' major shareholders?
TG Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.03%), Vanguard Group Inc. (4.59%), Sofinnova Investments Inc. (1.43%), Camber Capital Management LP (1.14%), Artal Group S.A. (1.02%) and Eversept Partners LP (1.00%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics.
Which institutional investors are selling TG Therapeutics stock?
TGTX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Bank of America Corp DE, D. E. Shaw & Co. Inc., A.R.T. Advisors LLC, Man Group plc, Virtus ETF Advisers LLC, Wells Fargo & Company MN and BNP Paribas Arbitrage SA. View Insider Buying and Selling for TG Therapeutics.
Which institutional investors are buying TG Therapeutics stock?
TGTX stock was bought by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Sofinnova Investments Inc., BlackRock Inc., Vanguard Group Inc., Nuveen Asset Management LLC, Eversept Partners LP, Renaissance Technologies LLC and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for TG Therapeutics.
How do I buy shares of TG Therapeutics?
Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TG Therapeutics' stock price today?
One share of TGTX stock can currently be purchased for approximately $6.68.
How big of a company is TG Therapeutics?
What is TG Therapeutics' official website?
How can I contact TG Therapeutics?
TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]
MarketBeat Community Rating for TG Therapeutics (NASDAQ TGTX)
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
